<p>Efficacy and Safety of Anlotinib for Elderly Patients with Previously Treated Extensive-Stage SCLC and the Prognostic Significance of Common Adverse Reactions</p>

Abstract

Background This study was to investigate the efficacy and safety of anlotinib for elderly patients with previously treated extensive-stage small cell lung cancer (ES-SCLC) and the prognostic significance of common adverse reactions. Patients and Methods A total of 79 elderly patients (≥60 years) with ES-SCLC who failed after at least two lines of previous systemic therapy were included. Baseline characteristics of the patients were collected. Follow-up was conducted regularly. Adverse reactions were documented. Survival curves were drawn using Kaplan–Meier method. Univariate analysis was assessed using log rank test, and multivariate analysis was adjusted by Cox regression analysis. Additionally, the prognostic significance of common adverse reactions was performed. Results All of the 79 patients were available for evaluation of efficacy. Partial response (PR) was observed in 7 patients, stable disease (SD) was noted in 48 patients and progressive disease (PD) was confirmed in 24 patients. Consequently, the objective response rate (ORR) was 8.9% and disease control rate (DCR) was 69.6%. The median progression-free survival (PFS) of the 79 elderly patients with ES-SCLC was 3.0 months [95% confidence interval (CI): 2.02–3.98]. The median overall survival (OS) was 7.1 months (95% CI: 5.07–9.13). Safety profile demonstrated that the relatively common adverse reactions of the elderly patients with ES-SCLC receiving anlotinib treatment were hypertension (40.5%), hand-foot syndrome (HFS, 31.6%), diarrhea (27.8%), decreased appetite (20.3%), fatigue (17.7%) and weight loss (17.7%). Interestingly, the prognostic significance of common adverse reactions indicated that the median PFS of patients with hypertension and without hypertension was 4.35 and 2.95 months, respectively ( P =0.01), and the median PFS of patients with HFS and without HFS was 4.20 and 2.95 months, respectively ( P =0.03). Conclusion The preliminary efficacy and safety of anlotinib in the treatment for elderly patients with previously treated ES-SCLC was satisfactory, and patients with hypertension and hand-foot syndrome might confer superior prognosis.

Efficacy and Safety of Regorafenib Monotherapy among Patients with Previously Treated Metastatic Colorectal Cancer in a Chinese Population: A Real-World Exploratory Study

“…Interestingly, the prognostic significance of adverse reactions in our study suggested that hypertension and HFS induced by regorafenib could be used as potential biomarkers to predict the prognosis of regorafenib treatment, which is in line with ae previous study of the association between HFS and regorafenib efficacy in the treatment of mCRC. 14 Similarly, a recent study using exploratory analysis to investigate the influence of HFS or hypertension on the efficacy of another antiangiogenic small-molecule TKI, anlotinib, for elderly patients with small-cell lung cancer 32 demonstrated that hypertension and HFS might confer superior PFS to no hypertension and HFS, consistent with the clinical significance of hypertension and HFS in our study. To our knowledge, hypertension and HFS are the most common adverse reactions associated with antiangiogenic inhibitors affecting on the VEGF pathway, including bevacizumab, sorafenib, and sunitinib.…”

Anlotinib Is Active for the Patients Failed From the Prior Antiangiogenic Therapy: Anti-angiogenic Therapy Might Be Cross-line Used

“…The incidence of adverse events recorded in both groups was low and similar to those reported in the literature [25,[40][41][42][43][44][45][46]. In this study, the proportion of patients rechecking ECG, thyroid function and urine routine was small.…”

Efficacy and Safety of Anlotinib Monotherapy as Third-Line Therapy for Elderly Patients with Non-Small Cell Lung Cancer: A Real-World Exploratory Study

“…26 Regarding the elderly patients with lung cancer who received anlotinib therapy, a previous study initiated by PF Song and colleagues included a total of 79 elderly patients with extensivestage small cell lung cancer aged 60 years old or above who were treated with 12 mg anlotinib monotherapy. 15 The results suggested that the preliminary efficacy and safety of anlotinib for elderly patients with previously treated ES-SCLC was satisfactory, which exhibited that patients with lung cancer could stand a good chance to benefit from anlotinib monotherapy. Overall response of anlotinib in elderly patients with advanced NSCLC exhibited that ORR and DCR were 7.2% and 78.3%, respectively.…”

“…The results of each imaging assessment were recorded and analyzed to document the best overall response of the patients. 15 Subsequently, follow-up was implemented using phone monthly, and the death status of the patients was mainly obtained through the communication with the relatives of the patients. The last follow-up date of the present study was July, 2021.…”